 SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL ACCESSWIRE April 19, 2021 NeoGenomics, Inc. NASDAQ:NEO, a leading provider of cancer-focused genetic testing services and global oncology contract research services, is excited to launch an Amgen-sponsored testing program to support single-gene molecular testing for the biomarker KRAS G12C for eligible lung cancer patients at no cost to the patient. 